Multidrug transporters are often responsible for failure of medical treatment, since they expel a variety of structurally and functionally unrelated drugs out of the cell. We found that the fluorescent probe diS-C3(3) is a substrate of not only Pdr5p of Saccharomyces cerevisiae (ScPdr5p) but also of its less-explored Kluyveromyces lactis homologue (KlPdr5p). This enabled us to compare the ability of azoles to competitively inhibit the Pdr5p-mediated probe efflux in the two species. In K. lactis, these azoles completely inhibit probe transport by KlPdr5p and also compete with each other for transport. This indicates that the probe and the azoles are bound by the same site(s) of the KlPdr5p binding pocket. On the other hand, the azoles' capacity to inhibit the probe transport by ScPdr5p is limited, as a result of their partial cotransport with the probe. While the azoles bind to only one or two separate binding sites, the probe is able to bind to all three of them. Moreover, the bulky ScPdr5p substrate enniatin B, which effectively inhibits both probe and azole transport by the pump, has negligible effect on KlPdr5p. Our data point to a tighter arrangement of the KlPdr5p binding pocket compared to that of ScPdr5p.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/femsyr/fox073 | DOI Listing |
Alzheimers Dement
December 2024
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Patiala, India.
Background: Neuroinflammation plays an important role in progression of Alzheimer's disease (AD). Interlukin-6 (IL-6) is well identified marker in initiating and regulating inflammation, and formation of senile plaques in brain. Therefore, simultaneous inhibition of both IL-6 and acetylcholinesterase (AChE) may be an effective strategy for AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute of Science and Technology Austria (ISTA), Klosterneuburg, Austria.
Background: We identified small molecule tricyclic pyrone compound CP2 as a mild mitochondrial complex I (MCI) inhibitor that induces neuroprotection in multiple mouse models of AD. One of the major concerns while targeting mitochondria is the production of reactive oxygen species (ROS). CP2 consists of two diastereoisomers, D1 and D2, with distinct activity and toxicity profiles.
View Article and Find Full Text PDFBackground: The increased incidence of Alzheimer's disease (AD) rate represent an unmet medical need and thus critical for the development of novel molecular therapeutics. Recent work focusing on patients with apoE4 alleles has highlighted the association of brain cholesterol dysregulation with elevated pathological burden and neurodegeneration. These studies have highlighted the importance of the nuclear receptor Liver X receptor (LXR) for developing AD therapies.
View Article and Find Full Text PDFBackground: Neurological disorders are at epidemic levels in the world today. Various proteins are being targeted for the development of novel molecular therapeutics; however, no small-molecule inhibitors have been discovered. Recent studies suggest that there are few molecules in clinical trials for various secretase (α, β, and γ), caspase, and calpain inhibitors.
View Article and Find Full Text PDFCurr Med Chem
January 2025
Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutcihe (STEBICEF) Università di Palermo, Via Archirafi 32, 90123 Palermo.
CDK2 plays a pivotal role in controlling the cell cycle progression in eukaryotes and for this reason, it has been the subject of several studies for suitable inhibitors in the last decades. But more than 30 years of basic research have not generated an inhibitor as marketed drugs. Some inhibitors are to date in early phase clinical development.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!